GSK plc (ADR)
General ticker "GSK" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $96.1B (TTM average)
GSK plc (ADR) follows the US Stock Market performance with the rate: 20.4%.
Estimated limits based on current volatility of 1.1%: low 49.92$, high 51.00$
Factors to consider:
- Company pays dividends (quarterly): last record date 2026-08-14, amount 0.45$ (Y3.57%)
- Total employees count: 99451 as of 2013
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [38.95$, 57.13$]
- 2026-12-31 to 2027-12-31 estimated range: [44.19$, 63.56$]
Financial Metrics affecting the GSK estimates:
- Negative: with PPE of 10.8 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 25.52 > 18.77
- Positive: 6.77 < Operating cash flow per share per price, % of 9.68
- Positive: Inventory ratio change, % of 0.02 <= 0.79
- Positive: Return on assets ratio (scaled to [-100,100]) of 8.57 > 6.06
- Positive: 18.97 < Shareholder equity ratio, % of 26.80 <= 42.26
- Positive: -14.39 < Investing cash flow per share per price, % of -7.76
- Positive: Industry earnings per price (median), % of 6.62 > 4.32
- Positive: Interest expense per share per price, % of 0.93 <= 3.34
Short-term GSK quotes
Long-term GSK plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | £30,328.00MM | £31,376.00MM | £32,667.00MM |
| Operating Expenses | £23,583.00MM | £27,355.00MM | £24,329.00MM |
| Operating Income | £6,745.00MM | £4,021.00MM | £8,338.00MM |
| Non-Operating Income | £-681.00MM | £-544.00MM | £-937.00MM |
| Interest Expense | £775.00MM | £657.58MM | £687.00MM |
| R&D Expense | £6,223.00MM | £6,401.00MM | £7,525.00MM |
| Income(Loss) | £6,064.00MM | £3,477.00MM | £7,401.00MM |
| Taxes | £756.00MM | £526.00MM | £1,112.00MM |
| Net Income(Loss)* | £4,928.00MM | £2,575.00MM | £5,716.00MM |
| Stockholders Equity | £17,014.76MM | £13,671.00MM | £16,348.21MM |
| Inventory | £7,008.85MM | £5,669.00MM | £5,913.59MM |
| Assets | £75,219.57MM | £59,463.00MM | £61,010.57MM |
| Operating Cash Flow | £7,890.89MM | £6,554.00MM | £7,142.96MM |
| Capital expenditure | £1,633.37MM | £2,982.00MM | £1,318.46MM |
| Investing Cash Flow | £-2,404.06MM | £-1,229.00MM | £-5,722.78MM |
| Financing Cash Flow | £-6,068.58MM | £-4,726.00MM | £-1,593.30MM |
| Earnings Per Share** | £2.43 | £1.26 | £2.82 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.